Latest Pharma Insights
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: J&J’s oncology prospects; GSK’s Rapt deal; 2026’s biggest expected launches; optimistic financial outlook at JPM; and Scrip Asks about the competitive dynamics landscape.
Scrip - January 26, 2026
In this week's episode: J&J’s oncology prospects; GSK’s Rapt deal; 2026’s biggest expected launches; optimistic financial outlook at JPM; and Scrip Asks about the competitive dynamics landscape.
Scrip - January 26, 2026
Halting Self-Affirmed GRAS Without Notification Tops Kennedy’s 2026 Food Safety ‘Deliverables’
FDA Human Foods Program’s list notes Kennedy’s GRAS focus as first item in “Food Chemical Safety” category, saying the agency in 2026 “will publish a proposed regulation to require the submission to FDA of GRAS notices for all substances claimed to be GRAS.”
HBW Insight - January 26, 2026
FDA Human Foods Program’s list notes Kennedy’s GRAS focus as first item in “Food Chemical Safety” category, saying the agency in 2026 “will publish a proposed regulation to require the submission to FDA of GRAS notices for all substances claimed to be GRAS.”
HBW Insight - January 26, 2026
Cipla Tackles Lanreotide Supply Woes, Solidifies India Diabetes Position
Lanreotide supply issues cloud Cipla’s Q3 FY26 earnings, with impact seen in Q4 as well, though pipeline assets augur well for US growth continuity. Perpetual rights to Novartis’s Galvus effective Jan 1, seen adding momentum to India diabetes gains.
Scrip - January 26, 2026
Lanreotide supply issues cloud Cipla’s Q3 FY26 earnings, with impact seen in Q4 as well, though pipeline assets augur well for US growth continuity. Perpetual rights to Novartis’s Galvus effective Jan 1, seen adding momentum to India diabetes gains.
Scrip - January 26, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: J&J’s oncology prospects; GSK’s Rapt deal; 2026’s biggest expected launches; optimistic financial outlook at JPM; and Scrip Asks about the competitive dynamics landscape.
Scrip - January 26, 2026
In this week's episode: J&J’s oncology prospects; GSK’s Rapt deal; 2026’s biggest expected launches; optimistic financial outlook at JPM; and Scrip Asks about the competitive dynamics landscape.
Scrip - January 26, 2026
Cipla Tackles Lanreotide Supply Woes, Solidifies India Diabetes Position
Lanreotide supply issues cloud Cipla’s Q3 FY26 earnings, with impact seen in Q4 as well, though pipeline assets augur well for US growth continuity. Perpetual rights to Novartis’s Galvus effective Jan 1, seen adding momentum to India diabetes gains.
Scrip - January 26, 2026
Lanreotide supply issues cloud Cipla’s Q3 FY26 earnings, with impact seen in Q4 as well, though pipeline assets augur well for US growth continuity. Perpetual rights to Novartis’s Galvus effective Jan 1, seen adding momentum to India diabetes gains.
Scrip - January 26, 2026
Intuitive Eyes Opportunities In Cardiac Care, Outpatient Centers
The FDA has cleared Intuitive Surgical’s da Vinci 5 for some cardiac procedures, opening new opportunities for the firm. The company is also looking to expand its presence in ambulatory surgical centers, execs said during a Jan. 22 earnings call.
Medtech Insight - January 24, 2026
The FDA has cleared Intuitive Surgical’s da Vinci 5 for some cardiac procedures, opening new opportunities for the firm. The company is also looking to expand its presence in ambulatory surgical centers, execs said during a Jan. 22 earnings call.
Medtech Insight - January 24, 2026
Halting Self-Affirmed GRAS Without Notification Tops Kennedy’s 2026 Food Safety ‘Deliverables’
FDA Human Foods Program’s list notes Kennedy’s GRAS focus as first item in “Food Chemical Safety” category, saying the agency in 2026 “will publish a proposed regulation to require the submission to FDA of GRAS notices for all substances claimed to be GRAS.”
HBW Insight - January 26, 2026
FDA Human Foods Program’s list notes Kennedy’s GRAS focus as first item in “Food Chemical Safety” category, saying the agency in 2026 “will publish a proposed regulation to require the submission to FDA of GRAS notices for all substances claimed to be GRAS.”
HBW Insight - January 26, 2026
BMS To Continue Legal Action As Zydus Launches First Cut-Price Nivolumab Biosimilar In India
BMS will continue to seek legal recourse even as Zydus Lifesciences launches the world’s first cut-price nivolumab biosimilar in India following a Delhi High Court division bench ruling in favor of the Indian company.
Generics Bulletin - January 23, 2026
BMS will continue to seek legal recourse even as Zydus Lifesciences launches the world’s first cut-price nivolumab biosimilar in India following a Delhi High Court division bench ruling in favor of the Indian company.
Generics Bulletin - January 23, 2026
Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - January 23, 2026
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - January 23, 2026
Towa, Otsuka Launch Cross-Sector Alliance For Long-Listed And Off-Patent Drugs
The leading Japanese generics player and local originator will collaborate on technology transfer, contract manufacturing and product succession as part of a cross-sector effort to strengthen supply chains for long-listed and off-patent medicines.
Generics Bulletin - January 23, 2026
The leading Japanese generics player and local originator will collaborate on technology transfer, contract manufacturing and product succession as part of a cross-sector effort to strengthen supply chains for long-listed and off-patent medicines.
Generics Bulletin - January 23, 2026
Podcast: Herantis’s ‘Elegant’ Approach In Parkinson’s
Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson’s disease and outlines Phase II plans for the company’s lead asset HER-096.
In Vivo - January 22, 2026
Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson’s disease and outlines Phase II plans for the company’s lead asset HER-096.
In Vivo - January 22, 2026
Priya Singhal’s Blueprint For Biogen’s Next Act
Biogen’s head of development reflects on transforming company strategy, surviving the Aduhelm crisis and building sustainable growth through disciplined portfolio management.
In Vivo - January 22, 2026
Biogen’s head of development reflects on transforming company strategy, surviving the Aduhelm crisis and building sustainable growth through disciplined portfolio management.
In Vivo - January 22, 2026
Medable Bets Agentic AI Can Crack Clinical Development’s Manual Labor Problem
Medable pivots to agentic AI targeting clinical development's 80% manual labor bottleneck, aiming to double CRA efficiency and unlock capacity for 9,000 waiting drug candidates.
In Vivo - January 22, 2026
Medable pivots to agentic AI targeting clinical development's 80% manual labor bottleneck, aiming to double CRA efficiency and unlock capacity for 9,000 waiting drug candidates.
In Vivo - January 22, 2026
Execs On The Move: December 2025
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - January 22, 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - January 22, 2026